Trial Profile
Effects of Lisdexamfetamine on Cognitive Control and Reward Response in Adolescents and Young Adults With ADHD: Neural and Clinical Outcomes
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms LEIA
- 10 Dec 2019 Status changed from completed to discontinued.
- 20 Jun 2017 Status changed from recruiting to completed.
- 16 Jul 2014 New trial record